Visit the ACCC COVID-19 Resource Center & Discussion Group for Insights on Providing Optimal Patient Care During the Pandemic.


Multidisciplinary Multiple Myeloma Care

Multiple myeloma, also known as myeloma, is a hematologic cancer (or cancer of the blood). Although multiple myeloma is the second most common blood cancer, after non-Hodgkin lymphoma, it is not a common cancer. The American Cancer Society estimates that 30,770 new cases of multiple myeloma will be diagnosed in 2018. Multiple myeloma is more common in men than women, and it occurs more frequently with increasing age, with the greatest incidence in those over age 70.


Project Goal

The main goal of this project is to raise awareness about provider education needs related to this patient population; to establish vetted, designated resources to help fill unmet needs; to help educate the cancer care team on effective practices in caring for patients with multiple myeloma; and to foster a network of engaged community cancer care professionals.

Specifically, this project is delivering:

  • an online hub of multiple myeloma resources for the multidisciplinary cancer care team curated by the project's Advisory Committee.
  • a case studies publication, highlighting effective practices being utilized to care for this unique patient population. To request print copies, please email
  • a series of educational sessions by presenters with expertise in multiple myeloma focused on peer-to-peer learning and discussion of updates in the field, new treatments and techniques, and local and regional resources. View the regional lecture series on demand.
  • a visiting experts workshop series—a one-day, personalized educational opportunity on implementing effective practices in treating multiple myeloma in the community setting—apply here!


Multidisciplinary-Multiple-Myeloma-Care-260x336Multidisciplinary Multiple Myeloma Care: Models of Effective Care Delivery

Multidisciplinary Multiple Myeloma Care: Models of Effective Care Delivery offers a convenient summary of recent updates in the management of this heterogeneous disease, including information on:

  • Diagnostic Criteria by the International Myeloma Working Group
  • Revised International Staging System
  • ASCO Clinical Practice Guideline Update: Role of Bone Modifying Agents in Multiple Myeloma

Plus, read how three cancer programs—a community-based comprehensive program, an academic medical center, and an NCI-designated program—are delivering multidisciplinary care to this patient population.
Download Publication

ACCC thanks the following member programs for their participation:

  • John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, New Jersey
  • Moffitt Cancer Center, Tampa, Florida
  • Yuma Regional Medical Center Cancer Center, Yuma, Arizona


Our Partner

Multiple Myeloma Research Foundation

Our Supporter

Amgen Oncology
Funding & support provided by Amgen Oncology